翔豐華(300890.SZ):年產6萬噸高端人造石墨負極材料項目擬落户遂寧蓬溪
格隆匯6月7日丨翔豐華(300890.SZ)公佈,基於聚焦新能源主業的戰略規劃和進一步完善公司佈局的需求,近日,公司與遂寧市蓬溪縣政府,為積極響應習近平總書記提出的“四個革命、一個合作”重大能源安全新戰略,促進遂寧市新能源產業發展,簽署了《關於建設年產能6萬噸高端人造石墨負極材料一體化生產基地建設項目的投資協議書》。
公司將在遂寧市蓬溪縣註冊成立控股子公司,生產石墨負極材料,年生產規模為6萬噸。計劃投資額度約為12億元(分兩期建設,一期計劃投資6億元,二期計劃投資6億元)。項目分兩期建設,一期建設週期約為20個月;二期項目在取得施工許可審批手續後16個月內建成投產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.